Clinical Trials Logo

Clinical Trial Summary

This is Phase I, 4-period, randomized, active-and placebo-controlled, double-blind crossover, single-dose study to evaluate the effects of a therapeutic (1000 milligram [mg]) and supratherapeutic (1800 mg) dose of GSK2140944 with a positive control (moxifloxacin 400 mg) and placebo on the corrected QT interval (QTc) as assessed by continuous 12-lead Holter electrocardiograms (ECGs) in approximately 55 healthy volunteers.

All subjects will receive single doses of GSK2140944 1000 mg, GSK2140944 1800 mg, moxifloxacin 400 mg, and placebo in a randomized sequence. A double-dummy approach will be used to maintain blinding. Thus, on each dosing day, moxifloxacin or moxifloxacin placebo and GSK2140944 or placebo will be administered.

Subjects will be screened within 30 days prior to entry to the clinic. Subjects will report to the clinical unit on Day -2 of Period 1 and on Day -1 in subsequent periods. Subjects will remain confined until check out procedures have been completed on Day 3 (5 days confinement in Period 1 and 4 days in the following 3 periods). There will be a washout of at least 7 days between doses. The follow-up visit will occur 7-10 days after the final dose. Total duration of the study (from screening to the follow-up visit) will be approximately 60 days.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02257398
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date October 6, 2014
Completion date March 2, 2015

See also
  Status Clinical Trial Phase
Completed NCT02202187 - A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers Phase 1
Completed NCT01706315 - This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects Phase 1
Completed NCT02000765 - A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects Phase 1
Completed NCT04600752 - Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India Phase 4
Terminated NCT01292213 - A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Children in United Kingdom N/A
Completed NCT01772238 - Bioequivalence Study of an Amoxicillin-Clavulanic Phase 1
Completed NCT01615796 - Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses Phase 1
Completed NCT02169583 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects Phase 1
Completed NCT01353768 - Zanamivir Aqueous Solution Compassionate Use Program Retrospective Chart Review Study N/A
Completed NCT01767532 - Bioequivalence Study of Cephalexin Suspension 125 Phase 1
Completed NCT01767571 - Bioequivalence Study of Cephalexin Suspension 250 Phase 1
Completed NCT01510938 - Probiotics in Respiratory Tract Infections in Children Phase 2
Completed NCT00354965 - Pharmacokinetic Profiles Of Amoxicillin 2000 mg And Clavulanate 125 mg In Adolescent Patients Phase 1
Completed NCT02688361 - A Bioequivalence Study of an Acetylcysteine 2% Oral Solution Versus a Reference Fluimucil 2% Oral Solution Phase 1
Withdrawn NCT02730364 - An Efficacy and Safety Study of Theraflu Night Powder as Oral Solution for Cold and Flu Phase 3
Withdrawn NCT02678234 - An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu Phase 3
Completed NCT01767584 - Bioequivalence Study of Cephalexin Tablets 1g Phase 1